The Right to Try Act and psychedelics: how patient access actually works in 2026

The federal Right to Try Act was signed in 2018. It gives terminally ill patients who have exhausted approved treatment options a pathway to request investigational drugs directly from a drug sponsor, without going through FDA expanded-access review. The law was used sparingly - roughly 10-20 documented cases in its first four years - because the FDA already runs a parallel Expanded Access (compassionate use) program that most sponsors prefer.

Until April 18, 2026, it had barely been used for psychedelics at all. The reason was operational: any Schedule I substance required separate DEA Schedule I research registration, and DEA had not built a Right to Try variant of that registration. The 2026 executive order directs FDA and DEA to fix that.

The law as it existed before the order

Right to Try eligibility under the 2018 Act requires four things. First, a diagnosis of a life-threatening disease or condition. Second, the patient must have exhausted approved treatment options and be unable to enroll in an ongoing clinical trial. Third, a licensed physician must certify the patient's eligibility and oversee care. Fourth, a drug sponsor must voluntarily agree to provide the investigational drug - there is no compelled-provision clause.

The law does not require FDA sign-off on the individual case. The sponsor ships the drug, the physician administers it, the sponsor reports the outcome to FDA annually.

Why it rarely applied to psychedelics

Even if an ibogaine sponsor and a patient both said yes, the patient's physician could not legally possess Schedule I ibogaine without a DEA Schedule I research registration tied to a specific protocol. Right to Try does not create that registration. This created a gap: the FDA side of the law was met, the DEA side was not.

The 2026 executive order tells DEA to write a companion rule. Expected draft text will likely create a narrow Schedule I access registration tied to the Right to Try diagnosis, with same-day reporting and physical security requirements similar to the existing Schedule I research registration.

Who qualifies

The most likely eligibility criteria, based on prior implementations and the executive order's language:

- Diagnosis of a serious mental illness in a category the order names: treatment-resistant depression, post-traumatic stress disorder, severe anxiety disorders, or (for ibogaine specifically) opioid use disorder with failed conventional treatment.

- Documentation of at least two failed approved treatments in the relevant class. For TRD that typically means two antidepressant trials, often plus ECT or TMS. For OUD it typically means methadone or buprenorphine failure.

- A physician certification covering the patient's inability to enroll in any ongoing FDA-reviewed trial of the same investigational drug.

- An active clinical program at a drug sponsor willing to provide the compound.

- Informed consent documenting that the drug is investigational, that safety and efficacy are not fully established, and that Right to Try administration is outside of FDA-regulated clinical oversight.

What sponsors have to do

Drug sponsors have three things they are not required by Right to Try to do, but effectively have to do anyway. Maintain a Right to Try policy and post it publicly (Section 561A of the FDCA, which amends the FFDCA). Supply the drug at cost-of-production or below (not a profit mechanism). Report annually to FDA on Right to Try use, adverse events, and outcomes.

In practice, many small-cap psychedelic sponsors will decline Right to Try requests because the administrative overhead is non-trivial and the clinical data from a single non-trial patient is of limited value to their IND. Expect the sponsors who do say yes to be those with strong veteran advocacy relationships (for ibogaine specifically), well-funded patient-access programs, or an existing compassionate-use infrastructure.

Not a consumer-access mechanism

This is the part that gets lost in press coverage. Right to Try is not a prescription shortcut. A patient cannot call their primary care doctor, ask for ibogaine, and expect to receive it within two weeks. Every confirmed Right to Try case in the law's history has been patient-initiated, physician-championed, sponsor-approved, and has taken 30-120 days of paperwork to execute. The psychedelic pathway will be the same.

Realistic timeline

Working back from comparable FDA + DEA joint rule-making cycles: a proposed rule should publish in 60-90 days, a 60-day public comment window follows, final rule in 90-120 days after that. First actual Right to Try psychedelic patient access is realistic in Q4 2026. Veteran-focused pathways through the VA will probably move faster because the VA can write its own administrative instructions without waiting for DEA rule-making.

What to do while waiting

Enroll in an active clinical trial if eligible. Speak to a licensed prescriber about approved options that may not have been fully tried (for TRD: Spravato + an unused augmentation class; for PTSD: prolonged exposure + a trialed SSRI; for OUD: methadone or buprenorphine). Do not self-source Schedule I compounds. If you are a veteran, contact the VA Mental Health office and ask specifically about the five existing psychedelic trials in NY, CA and OR.

We will update this page when the FDA and DEA draft rules publish.